Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Business Insider16d
Rhythm Pharmaceuticals gets orphan drug designation for setmelanotide in Japan
Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for setmelanotide as a treatment for acquired hypothalamic ...
Pharmabiz14d
Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan
Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan: Boston Friday, March 21, 2025, 16:00 Hrs [IST] Rhythm Pharmaceuticals, Inc ...
Yahoo Finance2d
Rhythm Pharmaceuticals, Inc. (RYTM)
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia a New registry study to focus on impact of fatigue in people with craniopharyngiomaBOSTON, March 18 ...
The Bakersfield Californian16d
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with ...
“Our global trial of setmelanotide in patients with acquired hypothalamic obesity – which is on track for topline data readout in the second quarter of 2025 – is being conducted in North ...
Yahoo Finance16d
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired ...
CNN4y
Rhythm Pharmaceuticals, Inc.
The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the ...
manilatimes15d
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
"Our global trial of setmelanotide in patients with acquired hypothalamic obesity - which is on track for topline data readout in the second quarter of 2025 - is being conducted in North America, ...
Nasdaq16d
Rhythm Pharmaceuticals Receives Orphan Drug Designation in Japan for Setmelanotide in Acquired Hypothalamic Obesity Treatment
Rhythm Pharmaceuticals, Inc. has announced that it received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for setmelanotide, a treatment aimed at acquired ...